1. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
- Author
-
Karla A. Fenton, Megan L. Heinrich, Donald S. Grant, Robert F. Garry, Mathew L Boisen, Mohamed Fullah, Viktoriya Borisevich, Mambu Momoh, Sheik Humarr Khan, Luis M. Branco, Robert W. Cross, Megan M. Rowland, Thomas W. Geisbert, Chad E. Mire, Daniel J. Deer, James E. Robinson, Augustine Goba, Krystle N. Agans, and Joan B. Geisbert
- Subjects
0301 basic medicine ,medicine.drug_class ,viruses ,Enzyme-Linked Immunosorbent Assay ,Cross Reactions ,Biology ,Antibodies, Viral ,Monoclonal antibody ,medicine.disease_cause ,Article ,General Biochemistry, Genetics and Molecular Biology ,West africa ,Random Allocation ,03 medical and health sciences ,Lassa Fever ,0302 clinical medicine ,medicine ,Animals ,Humans ,030212 general & internal medicine ,Lassa virus ,Lassa fever ,Monoclonal antibody therapy ,Immune Evasion ,Advanced stage ,Antibodies, Monoclonal ,virus diseases ,General Medicine ,Viral Load ,medicine.disease ,Antibodies, Neutralizing ,Immunohistochemistry ,Virology ,Survival Rate ,Macaca fascicularis ,030104 developmental biology ,Immunology ,biology.protein ,RNA, Viral ,Antibody ,Viral load - Abstract
There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.
- Published
- 2017